Early detection of liver injuries by the Serum enhanced binding test sensitive to albumin post-transcriptional modifications.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
16 Jan 2024
Historique:
received: 02 08 2023
accepted: 04 01 2024
medline: 17 1 2024
pubmed: 17 1 2024
entrez: 16 1 2024
Statut: epublish

Résumé

Early and sensitive biomarkers of liver dysfunction and drug-induced liver injury (DILI) are still needed, both for patient care and drug development. We developed the Serum Enhanced Binding (SEB) test to reveal post-transcriptional modifications (PTMs) of human serum albumin resulting from hepatocyte dysfunctions and further evaluated its performance in an animal model. The SEB test consists in spiking serum ex-vivo with ligands having specific binding sites related to the most relevant albumin PTMs and measuring their unbound fraction. To explore the hypothesis that albumin PTMs occur early during liver injury and can also be detected by the SEB test, we induced hepatotoxicity in male albino Wistar rats by administering high daily doses of ethanol and CCl

Identifiants

pubmed: 38228668
doi: 10.1038/s41598-024-51412-0
pii: 10.1038/s41598-024-51412-0
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1434

Informations de copyright

© 2024. The Author(s).

Références

Baldassarre, M. et al. Albumin homodimers in patients with cirrhosis: clinical and prognostic relevance of a novel identified structural alteration of the molecule. Sci Rep 6, 35987. https://doi.org/10.1038/srep35987 (2016).
doi: 10.1038/srep35987 pubmed: 27782157 pmcid: 5080612
Baldassarre, M. et al. Determination of effective albumin in patients with decompensated cirrhosis: Clinical and prognostic implications. Hepatology https://doi.org/10.1002/hep.31798 (2021).
doi: 10.1002/hep.31798 pubmed: 33710623
Das, S. et al. Hyperoxidized albumin modulates neutrophils to induce oxidative stress and inflammation in severe alcoholic hepatitis. Hepatology 65, 631–646. https://doi.org/10.1002/hep.28897 (2017).
doi: 10.1002/hep.28897 pubmed: 27775820
Domenicali, M. et al. Posttranscriptional changes of serum albumin: Clinical and prognostic significance in hospitalized patients with cirrhosis. Hepatology 60, 1851–1860. https://doi.org/10.1002/hep.27322 (2014).
doi: 10.1002/hep.27322 pubmed: 25048618
Jalan, R. et al. Alterations in the functional capacity of albumin in patients with decompensated cirrhosis is associated with increased mortality. Hepatology 50, 555–564. https://doi.org/10.1002/hep.22913 (2009).
doi: 10.1002/hep.22913 pubmed: 19642174
Kawakami, A. et al. Identification and characterization of oxidized human serum albumin. A slight structural change impairs its ligand-binding and antioxidant functions. FEBS J 273, 3346–3357. https://doi.org/10.1111/j.1742-4658.2006.05341.x (2006).
doi: 10.1111/j.1742-4658.2006.05341.x pubmed: 16857017
Klammt, S. et al. Albumin-binding function is reduced in patients with decompensated cirrhosis and correlates inversely with severity of liver disease assessed by model for end-stage liver disease. Eur J Gastroenterol Hepatol 19, 257–263. https://doi.org/10.1097/MEG.0b013e3280101f7d (2007).
doi: 10.1097/MEG.0b013e3280101f7d pubmed: 17301654
Naldi, M., Baldassarre, M., Domenicali, M., Bartolini, M. & Caraceni, P. Structural and functional integrity of human serum albumin: Analytical approaches and clinical relevance in patients with liver cirrhosis. J Pharm Biomed Anal 144, 138–153. https://doi.org/10.1016/j.jpba.2017.04.023 (2017).
doi: 10.1016/j.jpba.2017.04.023 pubmed: 28465079
Oettl, K. et al. Oxidative albumin damage in chronic liver failure: Relation to albumin binding capacity, liver dysfunction and survival. J Hepatol 59, 978–983. https://doi.org/10.1016/j.jhep.2013.06.013 (2013).
doi: 10.1016/j.jhep.2013.06.013 pubmed: 23811308
Spinella, R., Sawhney, R. & Jalan, R. Albumin in chronic liver disease: Structure, functions and therapeutic implications. Hepatol Int 10, 124–132. https://doi.org/10.1007/s12072-015-9665-6 (2016).
doi: 10.1007/s12072-015-9665-6 pubmed: 26420218
Stauber, R. E. et al. Human nonmercaptalbumin-2: A novel prognostic marker in chronic liver failure. Ther Apher Dial 18, 74–78. https://doi.org/10.1111/1744-9987.12024 (2014).
doi: 10.1111/1744-9987.12024 pubmed: 24499087
Fanali, G. et al. Human serum albumin: from bench to bedside. Mol Aspects Med 33, 209–290. https://doi.org/10.1016/j.mam.2011.12.002 (2012).
doi: 10.1016/j.mam.2011.12.002 pubmed: 22230555
Sun, L. et al. Albumin binding function is a novel biomarker for early liver damage and disease progression in non-alcoholic fatty liver disease. Endocrine 69, 294–302. https://doi.org/10.1007/s12020-020-02319-z (2020).
doi: 10.1007/s12020-020-02319-z pubmed: 32399892
Xiao, L.-L. et al. Using advanced oxidation protein products and ischaemia-modified albumin to monitor oxidative stress levels in patients with drug-induced liver injury. Sci Rep https://doi.org/10.1038/s41598-020-75141-2 (2020).
doi: 10.1038/s41598-020-75141-2 pubmed: 33335107 pmcid: 7747602
Chen, C.-Y., Tsai, W.-L., Lin, P.-J. & Shiesh, S.-C. The value of serum ischemia-modified albumin for assessing liver function in patients with chronic liver disease. Clinical Chemistry and Laboratory Medicine. https://doi.org/10.1515/cclm.2011.675 (2011).
doi: 10.1515/cclm.2011.675 pubmed: 22040238 pmcid: 3749089
Alcaraz-Quiles, J. et al. Oxidized albumin triggers a cytokine storm in leukocytes through P38 mitogen-activated protein kinase: Role in systemic inflammation in decompensated cirrhosis. Hepatology 68, 1937–1952. https://doi.org/10.1002/hep.30135 (2018).
doi: 10.1002/hep.30135 pubmed: 30070728
Casulleras, M. et al. Albumin internalizes and inhibits endosomal TLR signaling in leukocytes from patients with decompensated cirrhosis. Sci Transl Med https://doi.org/10.1126/scitranslmed.aax5135 (2020).
doi: 10.1126/scitranslmed.aax5135 pubmed: 33087502
de Franchis, R. et al. Baveno VII: Renewing consensus in portal hypertension. J Hepatol 76, 959–974. https://doi.org/10.1016/j.jhep.2021.12.022 (2022).
doi: 10.1016/j.jhep.2021.12.022 pubmed: 35120736
El Balkhi, S. et al. Human plasma copper proteins speciation by size exclusion chromatography coupled to inductively coupled plasma mass spectrometry. Solutions for columns calibration by sulfur detection. Anal Chem 82, 6904–6910. https://doi.org/10.1021/ac101128x (2010).
doi: 10.1021/ac101128x pubmed: 20704379
Lilley, E. et al. ARRIVE 2.0 and the British Journal of Pharmacology: Updated guidance for 2020. Brit J Pharmacol 177, 3611–3616. https://doi.org/10.1111/bph.15178 (2020).
doi: 10.1111/bph.15178
Curtis, M. J. et al. Experimental design and analysis and their reporting II: updated and simplified guidance for authors and peer reviewers. Brit J Pharmacol 175, 987–993. https://doi.org/10.1111/bph.14153 (2018).
doi: 10.1111/bph.14153
Rahali, M. A. et al. Posttranslational-modifications of human-serum-albumin analysis by a top-down approach validated by a comprehensive bottom-up analysis. J Chromatogr B Analyt Technol Biomed Life Sci 1224, 123740. https://doi.org/10.1016/j.jchromb.2023.123740 (2023).
doi: 10.1016/j.jchromb.2023.123740 pubmed: 37182409
Qi, J. et al. Developing anticancer ferric prodrugs based on the n-donor residues of human serum albumin carrier IIA subdomain. J Med Chem 59, 7497–7511. https://doi.org/10.1021/acs.jmedchem.6b00509 (2016).
doi: 10.1021/acs.jmedchem.6b00509 pubmed: 27441502
Eswar, N. et al. Comparative protein structure modeling using Modeller. Curr Protoc Bioinformatics https://doi.org/10.1002/0471250953.bi0506s15 (2006).
doi: 10.1002/0471250953.bi0506s15 pubmed: 18428767 pmcid: 4186674
Curry, S., Brick, P. & Franks, N. P. Fatty acid binding to human serum albumin: New insights from crystallographic studies. Biochim Biophys Acta 1441, 131–140. https://doi.org/10.1016/s1388-1981(99)00148-1 (1999).
doi: 10.1016/s1388-1981(99)00148-1 pubmed: 10570241
Fujiwara, S. & Amisaki, T. Identification of high affinity fatty acid binding sites on human serum albumin by MM-PBSA method. Biophys J 94, 95–103. https://doi.org/10.1529/biophysj.107.111377 (2008).
doi: 10.1529/biophysj.107.111377 pubmed: 17827235
Maier, J. A. et al. ff14SB: improving the accuracy of protein side chain and backbone parameters from ff99SB. J Chem Theory Comput 11, 3696–3713. https://doi.org/10.1021/acs.jctc.5b00255 (2015).
doi: 10.1021/acs.jctc.5b00255 pubmed: 26574453 pmcid: 4821407
MacKerell, A. D. et al. All-atom empirical potential for molecular modeling and dynamics studies of proteins. J Phys Chem B 102, 3586–3616. https://doi.org/10.1021/jp973084f (1998).
doi: 10.1021/jp973084f pubmed: 24889800
Price, D. J. & Brooks, C. L. A modified TIP3P water potential for simulation with Ewald summation. J Chem Phys 121, 10096–10103. https://doi.org/10.1063/1.1808117 (2004).
doi: 10.1063/1.1808117 pubmed: 15549884
Joung, I. S. & Cheatham, T. E. Molecular dynamics simulations of the dynamic and energetic properties of alkali and halide ions using water-model-specific ion parameters. J Phys Chem B 113, 13279–13290. https://doi.org/10.1021/jp902584c (2009).
doi: 10.1021/jp902584c pubmed: 19757835 pmcid: 2755304
Dickson, C. J. et al. Lipid14: The amber lipid force field. J Chem Theory Comput 10, 865–879. https://doi.org/10.1021/ct4010307 (2014).
doi: 10.1021/ct4010307 pubmed: 24803855 pmcid: 3985482
Irani, M. et al. Amino acid oxidation of Candida antarctica lipase B studied by molecular dynamics simulations and site-directed mutagenesis. Biochemistry 52, 1280–1289. https://doi.org/10.1021/bi301298m (2013).
doi: 10.1021/bi301298m pubmed: 23331091
Roe, D. R. & Cheatham, T. E. PTRAJ and CPPTRAJ: software for processing and analysis of molecular dynamics trajectory data. J Chem Theory Comput 9, 3084–3095. https://doi.org/10.1021/ct400341p (2013).
doi: 10.1021/ct400341p pubmed: 26583988
Hunter, J. D. Matplotlib: a 2D graphics environment. Comput Sci Eng 9, 90–95. https://doi.org/10.1109/mcse.2007.55 (2007).
doi: 10.1109/mcse.2007.55
Rodriguez, A. & Laio, A. Clustering by fast search and find of density peaks. Science 344, 1492–1496. https://doi.org/10.1126/science.1242072 (2014).
doi: 10.1126/science.1242072 pubmed: 24970081
Kang, P. W. et al. Calmodulin acts as a state-dependent switch to control a cardiac potassium channel opening. Sci Adv https://doi.org/10.1126/sciadv.abd6798 (2020).
doi: 10.1126/sciadv.abd6798 pubmed: 33328226 pmcid: 10662591
Li, Y., Yan, X. P., Chen, C., Xia, Y. L. & Jiang, Y. Human serum albumin-mercurial species interactions. J Proteome Res 6, 2277–2286. https://doi.org/10.1021/pr0700403 (2007).
doi: 10.1021/pr0700403 pubmed: 17489621
Shen, X. C. et al. Studies on the interaction between Ag(+) and human serum albumin. J Inorg Biochem 95, 124–130. https://doi.org/10.1016/s0162-0134(03)00094-1 (2003).
doi: 10.1016/s0162-0134(03)00094-1 pubmed: 12763656
Sokolowska, M., Wszelaka-Rylik, M., Poznanski, J. & Bal, W. Spectroscopic and thermodynamic determination of three distinct binding sites for Co(II) ions in human serum albumin. J Inorg Biochem 103, 1005–1013. https://doi.org/10.1016/j.jinorgbio.2009.04.011 (2009).
doi: 10.1016/j.jinorgbio.2009.04.011 pubmed: 19487034
Petitpas, I. et al. Structural basis of albumin–thyroxine interactions and familial dysalbuminemic hyperthyroxinemia. Proc. Natl. Acad. Sci. 100, 6440–6445. https://doi.org/10.1073/pnas.1137188100 (2003).
doi: 10.1073/pnas.1137188100 pubmed: 12743361 pmcid: 164465
Bar-Or, D., Lau, E. & Winkler, J. V. A novel assay for cobalt-albumin binding and its potential as a marker for myocardial ischemia-a preliminary report. J. Emerg. Med. 19, 311–315. https://doi.org/10.1016/s0736-4679(00)00255-9 (2000).
doi: 10.1016/s0736-4679(00)00255-9 pubmed: 11074321
Moghaddam, A. P., Eggers, J. S. & Calabrese, E. J. Evaluation of sex difference in tissue repair following acute carbon tetrachloride toxicity in male and female Sprague-Dawley rats. Toxicology 130, 95–105. https://doi.org/10.1016/s0300-483x(98)00095-x (1998).
doi: 10.1016/s0300-483x(98)00095-x pubmed: 9865477
Mao, S. A., Glorioso, J. M. & Nyberg, S. L. Liver regeneration. Transl. Res. 163, 352–362. https://doi.org/10.1016/j.trsl.2014.01.005 (2014).
doi: 10.1016/j.trsl.2014.01.005 pubmed: 24495569 pmcid: 3976740
Weber, L. W., Boll, M. & Stampfl, A. Hepatotoxicity and mechanism of action of haloalkanes: carbon tetrachloride as a toxicological model. Crit. Rev. Toxicol. 33, 105–136. https://doi.org/10.1080/713611034 (2003).
doi: 10.1080/713611034 pubmed: 12708612
Lakis, R. et al. Absolute quantification of Human Serum Albumin isoforms by internal calibration based on a top-down LC-MS approach. Anal. Chem. https://doi.org/10.1021/acs.analchem.3c03933 (2024).
doi: 10.1021/acs.analchem.3c03933 pubmed: 38166371

Auteurs

Souleiman El Balkhi (S)

P&T, UMR1248, Inserm, Univ. Limoges, Limoges, France. souleiman.elbalkhi@chu-limoges.fr.
Department of Pharmacology, Toxicology and Pharmacovigilance, CHU Limoges, Limoges, France. souleiman.elbalkhi@chu-limoges.fr.
Pharmacology-Toxicology and Pharmacovigilance Department, Centre de Biologie Et de Recherche en Santé (CBRS), 2, Av. Martin Luther King, 87042, Limoges Cedex, France. souleiman.elbalkhi@chu-limoges.fr.

Mohamad Ali Rahali (MA)

P&T, UMR1248, Inserm, Univ. Limoges, Limoges, France.
Department of Pharmacology, Toxicology and Pharmacovigilance, CHU Limoges, Limoges, France.

Roy Lakis (R)

P&T, UMR1248, Inserm, Univ. Limoges, Limoges, France.

François Ludovic Sauvage (FL)

P&T, UMR1248, Inserm, Univ. Limoges, Limoges, France.

Marving Martin (M)

P&T, UMR1248, Inserm, Univ. Limoges, Limoges, France.

Angelika Janaszkiewicz (A)

P&T, UMR1248, Inserm, Univ. Limoges, Limoges, France.

Roland Lawson (R)

P&T, UMR1248, Inserm, Univ. Limoges, Limoges, France.

Ruben Goncalves (R)

P&T, UMR1248, Inserm, Univ. Limoges, Limoges, France.

Paul Carrier (P)

P&T, UMR1248, Inserm, Univ. Limoges, Limoges, France.
Department of Liver Disease, CHU Limoges, Limoges, France.

Veronique Loustaud-Ratti (V)

P&T, UMR1248, Inserm, Univ. Limoges, Limoges, France.
Department of Liver Disease, CHU Limoges, Limoges, France.

Anne Guyot (A)

Department of Pathology, CHU Limoges, Limoges, France.

Pierre Marquet (P)

P&T, UMR1248, Inserm, Univ. Limoges, Limoges, France.
Department of Pharmacology, Toxicology and Pharmacovigilance, CHU Limoges, Limoges, France.

Florent Di Meo (F)

P&T, UMR1248, Inserm, Univ. Limoges, Limoges, France.

Franck Saint-Marcoux (F)

P&T, UMR1248, Inserm, Univ. Limoges, Limoges, France.
Department of Pharmacology, Toxicology and Pharmacovigilance, CHU Limoges, Limoges, France.

Classifications MeSH